- Home
- YMAB vs FDMT Comparison
YMAB vs FDMT Comparison
Compare YMAB & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YMAB
- FDMT
- Stock Information
- Founded
- YMAB 2015
- FDMT 2013
- Country
- YMAB United States
- FDMT United States
- Employees
- YMAB N/A
- FDMT N/A
- Industry
- YMAB Biotechnology: Pharmaceutical Preparations
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- YMAB Health Care
- FDMT Health Care
- Exchange
- YMAB Nasdaq
- FDMT Nasdaq
- Market Cap
- YMAB 270.5M
- FDMT 268.6M
- IPO Year
- YMAB 2018
- FDMT 2020
- Fundamental
- Price
- YMAB $5.72
- FDMT $4.64
- Analyst Decision
- YMAB Strong Buy
- FDMT Buy
- Analyst Count
- YMAB 10
- FDMT 10
- Target Price
- YMAB $21.10
- FDMT $36.33
- AVG Volume (30 Days)
- YMAB 542.6K
- FDMT 957.1K
- Earning Date
- YMAB 03-04-2025
- FDMT 03-03-2025
- Dividend Yield
- YMAB N/A
- FDMT N/A
- EPS Growth
- YMAB N/A
- FDMT N/A
- EPS
- YMAB N/A
- FDMT N/A
- Revenue
- YMAB $84,553,000.00
- FDMT $17,000.00
- Revenue This Year
- YMAB $6.41
- FDMT N/A
- Revenue Next Year
- YMAB $18.15
- FDMT $159.36
- P/E Ratio
- YMAB N/A
- FDMT N/A
- Revenue Growth
- YMAB N/A
- FDMT N/A
- 52 Week Low
- YMAB $5.60
- FDMT $4.41
- 52 Week High
- YMAB $20.90
- FDMT $36.25
- Technical
- Relative Strength Index (RSI)
- YMAB 35.08
- FDMT 40.01
- Support Level
- YMAB $5.60
- FDMT $4.41
- Resistance Level
- YMAB $6.57
- FDMT $5.42
- Average True Range (ATR)
- YMAB 0.38
- FDMT 0.48
- MACD
- YMAB 0.10
- FDMT -0.05
- Stochastic Oscillator
- YMAB 11.43
- FDMT 9.38
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.